arrow
J

Judit Matito

vall d'hebron institut d'oncologia (vhio)
H指数:16
被引数:1,016

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identifying germline pathogenic variants in breast cancer using tumor sequencing

通过肿瘤测序鉴定乳腺癌中的生殖系致病性变异

BREAST
IF7.9
2025-06-010
OAAI
Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression
2025-01-050
OAAI
Pan-cancer homologous recombination deficiency (HRD) evaluation in patients enrolled in a routine molecular screening program

泛癌种同源重组缺陷(HRD)在参与常规分子筛查项目的患者中的评估

2024-09-010
PRE
Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors

循环肿瘤DNA(ctDNA)下一代测序(NGS)的临床应用价值,以指导晚期实体瘤患者的治疗决策

2024-09-010
PRE
ctDNA-based DNADX in hormone receptorpositive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
2024-05-020
PRE
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
2024-03-018
OAAI
Early-Stage Breast Cancer Detection in Breast Milk
2023-09-1411
OAAI
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

血浆BRAF-V600E等位基因分数作为BRAF组合治疗转移性结直肠癌的预后因素

2023-06-0136
OA
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
2023-03-0123
OAAI
Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
2023-03-011
PRE
ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER
2023-03-010
PRE
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
2022-11-042
OAAI
Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors
2021-07-019
OAAI
DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
2020-09-010
PREAI
Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
2020-02-1432
OAAI
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
2020-02-0539
OAAI
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer

循环肿瘤DNA突变等位基因分数对RAS突变转移性结直肠癌预后的影响

2019-07-3147
OAAI